the market?
Gilead Sciences
NASDAQ: GILD
55.93
-0.54
(-0.96%)
| Today's Open | $57.00 |
|---|---|
| Previous Close | $56.47 |
| Daily Range | $55.62 - $58.07 |
| 52-Week Range | $24.12 - $58.07 |
| Market Cap | $85.3B |
| P/E Ratio | 31.55 |
| Dividend (Yield) | $0.00 (0.0%) |
| Volume | 12,766,148 |
| Average Daily Volume | 13,365,783 |
| Current FY EPS | $1.90 |
How do you think GILD
will perform against the market?
Top GILD Bull/Bear Pitches
CarolinaMatt (< 20)
Submitted
January 3, 2011
Yes I get it. This company is no longer the high-flying early-stage pharma star with a everything under patent and profits growing as fast as it can ramp distribution. But this is no old super-slow … More
stockfreak1 (19.13)
Submitted
July 24, 2010
With more and more HIV generics around the corner it's not surprising why the CEO is selling and selling quick. Anyone actually see the retail prices on their drugs? Good God Viread is like $12 a pill … More
News & Commentary
Tackling Cancer: Leukemia's Biggest Current and Upcoming Players
Cancer research is big business, and it pays to know where research dollars are headed.Pre-Market Most Active for May 22, 2013 : NTAP, PFE, NMR, RDS/A, RDS/B, NOK, SNE, PGTI, IRWD, GILD,
Pre-Market Most Active for May 22, 2013 : NTAP, PFE, NMR, RDS/A, RDS/B, NOK, SNE, PGTI, IRWD, GILD, VOD, ZNGA3 Upgrades on Friday Worth Noting
3 Upgrades on Friday Worth Noting3 Horrendous Health-Care Stocks This Week
The rising tide of the stock market didn't lift all boats.Sector
Healthcare
Industry
Drugs
Gilead Sciences (GILD) Description
Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide. Website: http://www.gilead.com/
CEO Rating by Glassdoor
More details for Gilead Sciences Jobs
Gilead Sciences reviews from employees
